New Delhi. The booster dose of Bharat Biotech’s Kovid-19 nasal vaccine iNCOVACC received Emergency Use Authorization (EUA) approval from the Drugs Controller General of India (DCGI) on Friday. According to the Hyderabad-based vaccine manufacturer, it has excellent immunization potential due to the organized immune system of the nasal mucosa. iNCOVACC is India’s first nasal vaccine, which has been developed for protection against Kovid-19.
According to CNBC-TV18 sources, the EUA is permitted for restricted emergency use as a third dose for adults, regardless of whether they have been given a dose of the Covaxin or Covishield vaccine. Intranasal inoculation of ChAd-SARS-CoV-2-S can induce an immune response in the nose, which is the point of entry for the virus. The booster dose will thus protect against disease, infection and transmission. The nasal vaccine can be taken six months after the second dose. It’s needleless, so it goes on easy.
Bharat Biotech claimed that the intranasal vaccine provokes a broad immune response and has the potential to block both infection and transmission of COVID-19. On 6 September, the DCGI approved its intranasal Covid vaccine iNCOVACC for restricted emergency use in those above 18 years of age.
As reported by ANI, Bharat Biotech had also applied for market authorization from DCGI for the intranasal heterologous booster. After Covishield and Covaxin, the vaccine will be given as a booster shot. India started giving booster doses to all adults from April 10 this year.
Is it necessary to take a booster dose?
Booster dose provides better protection from Kovid-19. The first two doses are still effective in preventing the development of severe disease, but they may become less effective over time. Especially in senior citizens and people suffering from serious diseases.
FIRST PUBLISHED : November 25, 2022, 19:15 IST